litlas
Log inCreate account

Julio C. Chávez

Active 2006–2025

Also published as
Julio C Chávez
128
Papers
19,076
Citations
54
h-index
118
i10-index

Citations

Citations per year for Julio C. Chávez1990: 1 citations1991: 1 citations1992: 1 citations2001: 3 citations2005: 1 citations2006: 4 citations2008: 3 citations2009: 1 citations2012: 4 citations2013: 2 citations2014: 7 citations2015: 12 citations2016: 11 citations2017: 40 citations2018: 140 citations2019: 625 citations2020: 1,062 citations2021: 1,360 citations2022: 1,291 citations2023: 1,056 citations2024: 1,732 citations2025: 816 citations2026: 11 citations1993–2000: no citations, so these years are not shown2002–2004: no citations, so these years are not shown2007: no citations, so this year is not shown2010–2011: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,623 citing papers, 31.2% of this breakdownChina: 912 citing papers, 10.8% of this breakdownGermany: 566 citing papers, 6.7% of this breakdownUnited Kingdom: 449 citing papers, 5.3% of this breakdownItaly: 417 citing papers, 5% of this breakdownFrance: 372 citing papers, 4.4% of this breakdownSpain: 349 citing papers, 4.2% of this breakdownCanada: 266 citing papers, 3.2% of this breakdownAustralia: 215 citing papers, 2.6% of this breakdownSwitzerland: 211 citing papers, 2.5% of this breakdownNetherlands: 178 citing papers, 2.1% of this breakdownJapan: 137 citing papers, 1.6% of this breakdown
0%31.2%Other 20.4%

Institutions

Fields

  • Medicine89.7%
  • Biochemistry, Genetics and Molecular Biology5.2%
  • Immunology and Microbiology3.3%
  • Engineering0.5%
  • Computer Science0.2%
  • Materials Science0.2%
  • Other0.9%

Topics

  • CAR-T cell therapy research25.2%
  • Lymphoma Diagnosis and Treatment8.6%
  • Virus-based gene therapy research6.1%
  • Immune Cell Function and Interaction4.9%
  • Nanowire Synthesis and Applications4.3%
  • Viral Infectious Diseases and Gene Expression in Insects3.6%
  • Other47.3%

Coauthors

All papers

Open in search
  1. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    Authors: Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Patrick J. Stiff, Jonathan W. Friedberg, Ian W. Flinn, André Goy, Brian T. Hill, Mitchell R. Smith, Abhinav Deol, Umar Farooq, Peter A. McSweeney, Javier Muñoz, Irit Avivi, Januario E. Castro, Jason R. Westin, Julio C. Chávez, Armin Ghobadi, Krishna V. Komanduri, Ronald Levy, Eric D. Jacobsen, Thomas E. Witzig, Patrick M. Reagan, Adrian Bot, John M. Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, David Chang, Jeff Wiezorek, William Y. Go - New England Journal of Medicine 2017 cited by 5,915

  2. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

    Authors: Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick J. Stiff, Ian W. Flinn, Umar Farooq, André Goy, Peter A. McSweeney, Javier Muñoz, Tanya Siddiqi, Julio C. Chávez, Alex F. Herrera, Nancy L. Bartlett, Jeffrey S. Wiezorek, Lynn Navale, Allen Xue, Yizhou Jiang, Adrian Bot, John M. Rossi, Jaeyeon Kim, William Y. Go, Sattva S. Neelapu - The Lancet Oncology 2018 cited by 2,251

  3. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

    Authors: Caron A. Jacobson, Julio C. Chávez, Alison R. Sehgal, Basem M. William, Javier Muñoz, Gilles Salles, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Ibrahim Yakoub‐Agha, Olalekan O. Oluwole, Henry C. Fung, Joseph D. Rosenblatt, John M. Rossi, Lovely Goyal, Vicki Plaks, Yin Yang, Remus Vezan, Mauro P. Avanzi, Sattva S. Neelapu - The Lancet Oncology 2021 cited by 617

  4. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

    Authors: Nathan Fowler, Michael Dickinson, Martin Dreyling, Joaquín Martínez‐López, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chávez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, José Antonio Pérez‐Simón, Andy I. Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andrés J.M. Ferreri, Takanori Teshima, Piers Patten, Joseph P. McGuirk, Andreas Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J. Schuster, Catherine Thiéblemont - Nature Medicine 2021 cited by 527

  5. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

    Authors: Loretta J. Nastoupil, Michael D. Jain, Lei Feng, Jay Y. Spiegel, Armin Ghobadi, Yi Lin, Saurabh Dahiya, Matthew A. Lunning, Lazaros J. Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph P. McGuirk, Abhinav Deol, Alison R. Sehgal, André Goy, Brian T. Hill, Khoan Vu, Charalambos Andreadis, Javier Muñoz, Jason R. Westin, Julio C. Chávez, Amanda F. Cashen, N. Nora Bennani, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Frederick L. Locke - Journal of Clinical Oncology 2020 cited by 786

  6. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)

    Authors: Sattva S. Neelapu, Caron A. Jacobson, Armin Ghobadi, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick J. Stiff, Ian W. Flinn, Umar Farooq, André Goy, Peter A. McSweeney, Javier Muñoz, Tanya Siddiqi, Julio C. Chávez, Alex F. Herrera, Nancy L. Bartlett, Adrian A. Bot, Rhine R. Shen, Jinghui Dong, Kanwarjit Singh, Harry Miao, Jaeyeon Kim, Yan Zheng, Frederick L. Locke - Blood 2023 cited by 228

  7. Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

    Authors: Rajat Bannerji, Jon E Arnason, Ranjana H Advani, Jennifer R Brown, John N Allan, Stephen M Ansell, Jeffrey A Barnes, Susan M O'Brien, Julio C Chávez, Johannes Duell, Andreas Rosenwald, Jennifer L Crombie, Melanie Ufkin, Jingjin Li, Min Zhu, Srikanth R Ambati, Aafia Chaudhry, Israel Lowy, Max S Topp - The Lancet Haematology 2022 cited by 237

  8. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial

    Authors: Sattva S. Neelapu, Michael Dickinson, Javier Muñoz, Matthew L. Ulrickson, Catherine Thiéblemont, Olalekan O. Oluwole, Alex F. Herrera, Chaitra S. Ujjani, Yi Lin, Peter A. Riedell, Natasha Kekre, Sven de Vos, Christine Lui, Francesca Milletti, Jinghui Dong, Hairong Xu, Julio C. Chávez - Nature Medicine 2022 cited by 283

  9. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma

    Authors: Jennifer M. Logue, Elisa Zucchetti, Christina A. Bachmeier, Gabriel Krivenko, Victoria S. Larson, Daniel Ninh, Giovanni Grillo, Biwei Cao, Jongphil Kim, Julio C. Chávez, Aliyah Baluch, Farhad Khimani, Aleksandr Lazaryan, Taiga Nishihori, Hien Liu, Javier Pinilla‐Ibarz, Bijal Shah, Rawan Faramand, Anna E. Coghill, Marco L. Davila, Bhagirathbhai Dholaria, Michael D. Jain, Frederick L. Locke - Haematologica 2020 cited by 271

  10. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

    Authors: Michael D. Jain, Hua Zhao, Xuefeng Wang, Reginald Atkins, Meghan Menges, Kayla Reid, Kristen Spitler, Rawan Faramand, Christina A. Bachmeier, Erin Dean, Biwei Cao, Julio C. Chávez, Bijal Shah, Aleksandr Lazaryan, Taiga Nishihori, Mohammed Hussaini, Ricardo J. Gonzalez, John E. Mullinax, Paulo C. Rodrı́guez, José R. Conejo-García, Claudio Anasetti, Marco L. Davila, Frederick L. Locke - Blood 2021 cited by 292

  11. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)

    Authors: Raza M. Alvi, Matthew J. Frigault, Michael G. Fradley, Michael D. Jain, Syed Mahmood, Magid Awadalla, Dae Hyun Lee, Daniel A. Zlotoff, Lili Zhang, Zsófia D. Drobni, Malek Hassan, Emmanuel Bassily, Isaac Rhea, Roohi Ismail‐Khan, Connor P. Mulligan, Dahlia Banerji, Aleksandr Lazaryan, Bijal Shah, Adam Rokicki, Noopur Raje, Julio C. Chávez, Jeremy S. Abramson, Frederick L. Locke, Tomas G. Neilan - Journal of the American College of Cardiology 2019 cited by 344

  12. Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma

    Authors: Frederick L. Locke, Sattva S. Neelapu, Nancy L. Bartlett, Tanya Siddiqi, Julio C. Chávez, Chitra Hosing, Armin Ghobadi, Lihua E. Budde, Adrian Bot, John M. Rossi, Yizhou Jiang, Allen Xue, Meg Elias, Jeff Aycock, Jeff Wiezorek, William Y. Go - Molecular Therapy 2017 cited by 619

  13. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma

    Authors: Erin Dean, Rahul Mhaskar, Hong Lü, Mina Mousa, Gabriel Krivenko, Aleksandr Lazaryan, Christina A. Bachmeier, Julio C. Chávez, Taiga Nishihori, Marco L. Davila, Farhad Khimani, Hien Liu, Javier Pinilla‐Ibarz, Bijal Shah, Michael D. Jain, Yoganand Balagurunathan, Frederick L. Locke - Blood Advances 2020 cited by 242

  14. Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5)

    Authors: Sattva S. Neelapu, Julio C. Chávez, Alison R. Sehgal, Narendranath Epperla, Matthew L. Ulrickson, Emmanuel Bachy, Pashna N. Munshi, Carla Casulo, David G. Maloney, Sven de Vos, Ran Reshef, Lori A. Leslie, Olalekan O. Oluwole, Ibrahim Yakoub‐Agha, Rashmi Khanal, Joseph D. Rosenblatt, Ronald L. Korn, Weixin Peng, Christine Lui, Jacob Wulff, Rhine R. Shen, Soumya Poddar, A. Scott Jung, Harry Miao, Sara Beygi, Caron A. Jacobson - Blood 2023 cited by 141

  15. Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial

    Authors: Lihua E. Budde, Adam J. Olszewski, Sarit Assouline, Izidore S. Lossos, Catherine Diefenbach, Manali Kamdar, Nilanjan Ghosh, Dipenkumar Modi, Waleed Sabry, Seema Naik, Amitkumar Mehta, Shazia K. Nakhoda, Stephen D. Smith, Kathleen Dorritie, Ting Jia, Song Pham, Ling‐Yuh Huw, Jing Jing, Hao Wu, Wahib S. Ead, Iris To, Connie Lee Batlevi, Michael C. Wei, Julio C. Chávez - Nature Medicine 2023 cited by 88

  16. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

    Authors: Martin Dreyling, Nathan Fowler, Michael Dickinson, Joaquín Martínez‐López, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chávez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie José Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, José Antonio Pérez‐Simón, Andy I. Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andrés J.M. Ferreri, Takanori Teshima, Piers Patten, Joseph P. McGuirk, Andreas Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Inès Paule, Aiesha Zia, Rakesh Awasthi, Xia Han, Davide Germano, Darragh O’Donovan, Roberto Ramos, Harald J. Maier, Aisha Masood, Catherine Thiéblemont, Stephen J. Schuster - Blood 2024 cited by 93

  17. CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products

    Authors: Julio C. Chávez, Christina A. Bachmeier, Mohamed A. Kharfan‐Dabaja - Therapeutic Advances in Hematology 2019 cited by 223

  18. Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma

    Authors: Austin J. Sim, Michael D. Jain, Nicholas Figura, Julio C. Chávez, Bijal Shah, Farhad Khimani, Aleksandr Lazaryan, Gabriel Krivenko, Marco L. Davila, Hien Liu, Aaron D. Falchook, Saurabh Dahiya, Aaron P. Rapoport, Sungjune Kim, Frederick L. Locke, Timothy J. Robinson - International Journal of Radiation Oncology*Biology*Physics 2019 cited by 162

  19. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis

    Authors: Adam M. Petrich, Mitul Gandhi, Borko Jovanovic, Jorge J. Castillo, Saurabh Rajguru, David T. Yang, Khushboo Shah, Jeremy D. Whyman, Frederick Lansigan, Francisco J. Hernandez‐Ilizaliturri, Lisa X. Lee, Stefan K. Barta, Shruthi Melinamani, Reem Karmali, Camille Adeimy, Scott E. Smith, Neil Dalal, Chadi Nabhan, David Peace, Julie M. Vose, Andrew M. Evens, Namrata Shah, Timothy S. Fenske, Andrew D. Zelenetz, Daniel J. Landsburg, Christina Howlett, Anthony R. Mato, Michael Jaglal, Julio C. Chávez, Judy Tsai, Nishitha Reddy, Shaoying Li, Caitlin E. Handler, Christopher R. Flowers, Jonathon B. Cohen, Kristie A. Blum, Kevin Song, Haowei Sun, Oliver W. Press, Ryan D. Cassaday, Jesse Jaso, L. Jeffrey Medeiros, Aliyah R. Sohani, Jeremy S. Abramson - Blood 2014 cited by 466

  20. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma

    Authors: Mahmoud Elsawy, Julio C. Chávez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman, Kelly Davison, Jakob Rudzki, Saurabh Dahiya, Kathleen Dorritie, Samantha Jaglowski, John Radford, Franck Morschhauser, David Cunningham, Alejandro Martı́n, Dimitrios Tzachanis, Matthew L. Ulrickson, Reem Karmali, Natasha Kekre, Catherine Thiéblemont, Gunilla Enblad, Peter Dreger, Ram Malladi, Namita Joshi, Wei‐Jhih Wang, Caitlyn T. Solem, Julia Thornton Snider, Paul Cheng, Christina To, Marie José Kersten - Blood 2022 cited by 75

  21. Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

    Authors: Michael D. Jain, Jay Y. Spiegel, Loretta J. Nastoupil, John Tamaresis, Armin Ghobadi, Yi Lin, Lazaros J. Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph P. McGuirk, Abhinav Deol, Kathleen Dorritie, Alison R. Sehgal, André Goy, Brian T. Hill, Charalambos Andreadis, Javier Muñoz, Matthew L. Ulrickson, Jason R. Westin, Julio C. Chávez, Dilan A. Patel, Miriam T. Jacobs, Radhika Bansal, N. Nora Bennani, Vivek Patel, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Frederick L. Locke, Matthew A. Lunning, Saurabh Dahiya - Journal of Clinical Oncology 2024 cited by 73

  22. Cytokine Release Syndrome: Current Perspectives

    Authors: Hemant S. Murthy, Madiha Iqbal, Julio C. Chávez, Mohamed A. Kharfan‐Dabaja - ImmunoTargets and Therapy 2019 cited by 176

  23. Umbralisib, a Dual PI3Kδ/CK1ε Inhibitor in Patients With Relapsed or Refractory Indolent Lymphoma

    Authors: Nathan Fowler, Felipe Samaniego, Wojciech Jurczak, Nilanjan Ghosh, Enrico Derenzini, James A. Reeves, Wanda Knopińska‐Posłuszny, Chan Y. Cheah, Tycel Phillips, Ewa Lech‐Marańda, Bruce D. Cheson, Paolo F. Caimi, Sebastian Grosicki, Lori A. Leslie, Julio C. Chávez, Gustavo Fonseca, Sunil Babu, Daniel J. Hodson, Spencer H. Shao, John M. Burke, Jeff P. Sharman, Jennie Y. Law, John M. Pagel, Hari P. Miskin, Peter Sportelli, Owen A. O’Connor, Michael Weiss, Pier Luigi Zinzani - Journal of Clinical Oncology 2021 cited by 161

  24. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions

    Authors: Victor M. Orellana‐Noia, Daniel Reed, Ashley McCook, Jeremy Sen, Christian Barlow, Mary‐Kate Malecek, Marcus P. Watkins, Brad S. Kahl, Michael A. Spinner, Ranjana H. Advani, Timothy Voorhees, Anson Snow, Natalie S. Grover, Amy Ayers, Jason T. Romancik, Yuxin Liu, Scott F. Huntington, Julio C. Chávez, Hayder Saeed, Aleksandr Lazaryan, Vikram Raghunathan, Stephen E. Spurgeon, Thomas Ollila, Christopher Del Prete, Adam J. Olszewski, Emily C. Ayers, Daniel J. Landsburg, Benjamin Echalier, Jun Lee, Manali Kamdar, Paolo F. Caimi, Timothy Fu, Jieqi Liu, Kevin A. David, Hanan Alharthy, Jennie Y. Law, Reem Karmali, Harsh Shah, Deborah M. Stephens, Ajay Major, Alexandra E. Rojek, Sonali M. Smith, Amulya Yellala, Avyakta Kallam, Shazi Nakhoda, Nadia Khan, Mohammad Sohail, Brian T. Hill, Odeth Barrett-Campbell, Frederick Lansigan, Jeffrey M. Switchenko, Jonathon B. Cohen, Craig A. Portell - Blood 2021 cited by 94